The Labelling Standard is designed to reduce the risk of patient harm from injectable medicines by helping healthcare professionals identify the correct injectable medicine or fluid (container), route of administration of the injectable medicine (conduit) and patient for whom the medicine is intended.

This document presents the second edition of the National Safety and Quality Health Service (NSQHS) Standards released in November 2017 and updated in May 2021.

The Commission has revised the National Tall Man Lettering List to include cloBAZam in the benzodiazepine class of medicines, based on the reporting of adverse events and near misses and its high similarity and likelihood of confusion with another benzodiazepine: CLONAZepam.

The purpose of this guide is to provide a consistent national framework for clinical governance that is based on the National Safety and Quality Health Service Standards.